

Targeting of Mitochondrial Protein Magmas Enhances Sensitivity to GBM Treatment

Scientific Retreat | November 8, 2024

Javier Lepe


PI: Daniela Bota, MD, PhD

Targeting of Mitochondrial Protein Magma Enhances Sensitivity to GBM Treatment

Highly aggressive malignant Brain cancer
Incidence 3 in 100,000 people in the U.S.



Median survival: 14.6 months



Radiation



Surgery

Standard of Care



Chemotherapy (TMZ)




Tumor Treating Fields (DeNovo)

*Clinical trials for new treatments fail to meet their primary endpoints

Targeting of Mitochondrial Protein Magma Enhances Sensitivity to GBM Treatment

Radiation / Chemotherapy



Resistance mechanisms

- DNA damage repair
- Glioma stem cells
- Tumor heterogeneity
- Mitochondrial reprogramming*


Research Focus

Role of MAGMAS in treatment resistance

MAGMAS - ~13kDa Mitochondrial Protein
Highly expressed in GBM

Regulates protein trafficking in the mitochondria
Inhibition with BT9 and KD sensitizes cells to treatments

Protein Trafficking Pathway



Thank You
